Epigenetic regulation of protein translation in KMT2A-rearranged AML
A. Lenard, H. M. Xie, S. S. Riedel, Z.-F. Yuan, N. Zhu, T. Neff, K. M. Bernt
Abstract
Inhibition of the histone methyl-transferase DOT1L (KMT4) has shown encouraging activity in preclinical models of KMT2A (MLL)-rearranged leukemia. The DOT1L inhibitor pinometostat (EPZ5676) was well tolerated in early phase clinical trials and showed modest clinical activity, including occasional complete responses (CRs) as single agent. These studies support the development of combinatorial therapies for KMT2A-rearranged leukemias. Here, we investigated two novel combinations: dual inhibition of the histone methyltransferases DOT1L and EZH2, and the combination of a DOT1L inhibitor with the protein synthesis inhibitor homoharringtonine (HHR).\n\nEZH2 is the catalytic histone methyltransferase in the polycomb repressive complex 2 (PRC2), and inhibition of EZH2 has reported preclinical activity in KMT2A-rearranged leukemia. We found that the H3K79 and H3K27 methyl marks are not dependent on each other, and that DOT1L and EZH2 inhibition affect largely distinct gene expression programs. In particular, the KMT2A/DOT1L target HOXA9, which is commonly de-repressed as a consequence of PRC2 loss or inhibition in other contexts, was not re-activated upon dual DOT1L/EZH2 knockout or inhibition. Despite encouraging data in murine KMT2A-MLLT3 transformed cells suggesting synergy between DOT1L and EZH2 inhibition, we found both synergistic and antagonistic effects on a panel of human KMT2A rearranged cell lines. Combinatorial inhibition of DOT1L and EZH2 is thus not a promising strategy. We identified opposing effects on ribosomal gene transcription and protein translation by DOT1L and EZH2 as a mechanism that is partially responsible for observed antagonistic effects. The effects of DOT1L inhibition on ribosomal gene expression prompted us to evaluate the combination of EPZ5676 with a protein translation inhibitor. EPZ5676 was synergistic with the protein translation inhibitor homoharringtonine (HHR), supporting further preclinical/clinical development of this combination.
02 /Specification & Classification
Click any tag to browse matching papersReproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- DNMT1-Mediated Epigenetic Reprogramming Drives KMT2A Amplifications and Rearrangements
Madison A. Lineberger, Zach H. Gray, … Johnathan R. Whetstine·bioRxiv·Sep 22, 2026
- Combined Menin and XPO1 inhibition drive synergistic antileukemic activity in KMT2Ar and NPM1-m AML
Md. Hafiz Uddin, Sandhya Dhiman, … Suresh Kumar Balasubramanian·bioRxiv·Mar 13, 2026
- KMT2A oncoproteins induce epigenetic resistance to targeted therapies
Derek H. Janssens, Melodie Duran, … Steven Henikoff·Nature CommunicationsPeer-reviewed·Oct 29, 2024
- Integrative phosphoproteomics defines two biologically distinct groups of KMT2A rearranged acute myeloid leukaemia with different drug response phenotypes
Pedro Casado, Ana Rio‐Machín, … Pedro R. Cutillas·Signal Transduction and Targeted TherapyPeer-reviewed·Feb 26, 2023
- Clonal evolution mediates Menin-inhibitor resistance in KMT2A-rearranged leukemias.
L. Mahdavi, H. Goodrow, … K. M. Bernt·bioRxiv·Mar 16, 2023
- The nuclear oncoprotein SET is necessary for MLL/KMT2A binding and transcriptional elongation.
María-Paz García-Cuéllar, Robert K. Slany·bioRxiv·Feb 28, 2026